69 results
PRER14A
BXRX
Baudax Bio, Inc.
25 Aug 23
Preliminary revised proxy
4:01pm
of cytokine release syndrome and neurotoxicity, and adverse events have resulted in the death of patients. Certain of our product candidates, such as TI-168 … from T cell therapy may be complicated and difficult to manage, which could result in patient death or other significant issues. Additionally, it can
DEFA14A
EX-99.2
BXRX
Baudax Bio, Inc.
9 Aug 23
Additional proxy soliciting materials
5:28pm
of cytokine release syndrome and neurotoxicity, and adverse events have resulted in the death of patients. Certain of our product candidates, such as TI … to manage, which could result in patient death or other significant issues. Additionally, it can be difficult to determine if the serious adverse
8-K/A
EX-99.2
BXRX
Baudax Bio, Inc.
9 Aug 23
Other Events
5:27pm
of cytokine release syndrome and neurotoxicity, and adverse events have resulted in the death of patients. Certain of our product candidates, such as TI … to manage, which could result in patient death or other significant issues. Additionally, it can be difficult to determine if the serious adverse
DEFA14A
jlvozg3p5wteaygb5t
5 Jul 23
Additional proxy soliciting materials
5:28pm
8-K
3nf8bje
5 Jul 23
Entry into a Material Definitive Agreement
5:26pm
8-K
EX-2.1
i9d4 9mhv9fn
5 Jul 23
Entry into a Material Definitive Agreement
5:26pm
8-K
qifnv2a
27 Jun 23
Submission of Matters to a Vote of Security Holders
4:05pm
424B3
puf5q06 jd8xbnk
28 Apr 23
Prospectus supplement
4:02pm
8-K
EX-99.1
8690k
23 Aug 22
Regulation FD Disclosure
9:02am
8-K
5aw cn5kkxopk
20 May 22
Submission of Matters to a Vote of Security Holders
4:07pm
8-K
EX-99.1
hblcrdng 5p6wov
20 Apr 22
Regulation FD Disclosure
8:34am